489 related articles for article (PubMed ID: 34986352)
1. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA.
Zhang X; Jin H; Huang X; Chaurasiya B; Dong D; Shanley TP; Zhao YY
Cell Rep; 2022 Jan; 38(1):110196. PubMed ID: 34986352
[TBL] [Abstract][Full Text] [Related]
2. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
[TBL] [Abstract][Full Text] [Related]
3. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
4. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma.
Liang C; Li F; Wang L; Zhang ZK; Wang C; He B; Li J; Chen Z; Shaikh AB; Liu J; Wu X; Peng S; Dang L; Guo B; He X; Au DWT; Lu C; Zhu H; Zhang BT; Lu A; Zhang G
Biomaterials; 2017 Dec; 147():68-85. PubMed ID: 28938163
[TBL] [Abstract][Full Text] [Related]
5. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
6. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
Liu W; Yang C; Liu Y; Jiang G
Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
[TBL] [Abstract][Full Text] [Related]
9. Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays.
Kurata M; Wolf NK; Lahr WS; Weg MT; Kluesner MG; Lee S; Hui K; Shiraiwa M; Webber BR; Moriarity BS
PLoS One; 2018; 13(9):e0198714. PubMed ID: 30222773
[TBL] [Abstract][Full Text] [Related]
10. gRNA-transient expression system for simplified gRNA delivery in CRISPR/Cas9 genome editing.
Easmin F; Hassan N; Sasano Y; Ekino K; Taguchi H; Harashima S
J Biosci Bioeng; 2019 Sep; 128(3):373-378. PubMed ID: 31010727
[TBL] [Abstract][Full Text] [Related]
11. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles.
Liu J; Chang J; Jiang Y; Meng X; Sun T; Mao L; Xu Q; Wang M
Adv Mater; 2019 Aug; 31(33):e1902575. PubMed ID: 31215123
[TBL] [Abstract][Full Text] [Related]
12. Efficient Editing of the Nuclear
Guzmán-Zapata D; Sandoval-Vargas JM; Macedo-Osorio KS; Salgado-Manjarrez E; Castrejón-Flores JL; Oliver-Salvador MDC; Durán-Figueroa NV; Nogué F; Badillo-Corona JA
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30871076
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9 in genome editing: Its function and medical applications.
Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
16. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
Bai B; Myklebust JH; Wälchli S
Methods Mol Biol; 2020; 2115():445-454. PubMed ID: 32006416
[TBL] [Abstract][Full Text] [Related]
17. Fabrication and characterization of PLGA nanoparticles encapsulating large CRISPR-Cas9 plasmid.
Jo A; Ringel-Scaia VM; McDaniel DK; Thomas CA; Zhang R; Riffle JS; Allen IC; Davis RM
J Nanobiotechnology; 2020 Jan; 18(1):16. PubMed ID: 31959180
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas systems: ushering in the new genome editing era.
Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
[TBL] [Abstract][Full Text] [Related]
19. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
[TBL] [Abstract][Full Text] [Related]
20. An Era of CRISPR/ Cas9 Mediated Plant Genome Editing.
Khurshid H; Jan SA; Shinwari ZK; Jamal M; Shah SH
Curr Issues Mol Biol; 2018; 26():47-54. PubMed ID: 28879855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
